芝加哥大学医学研究人员开发了一种新的风险评分 US-CRS，用于预测未经心脏移植的死亡，旨在改进当前的 6 状态系统。 University of Chicago Medicine researchers developed a new risk score, US-CRS, for predicting death without heart transplant, aiming to improve upon the current 6-status system.
由芝加哥大学医学专家领导的一个研究小组开发了一种新的风险评分，旨在预测患者在不进行心脏移植的情况下死亡的可能性。 A research team led by experts at the University of Chicago Medicine has developed a new risk score designed to predict the likelihood that a patient will die without a heart transplant. 这项创新旨在解决当前基于治疗的 6 状态系统的局限性，提供一种更精确、更公平的方法来根据医疗紧急程度对候选人进行优先级排序。 This innovation aims to address the limitations of the current therapy-based 6-status system, offering a more precise and fair approach to prioritizing candidates based on medical urgency. 研究小组于 2024 年 2 月在《美国医学会杂志》上发表了他们的研究结果。 The research team published their findings in JAMA in February 2024. 新的风险评分，称为美国 The new risk score, called the U.S. 在 2019 年至 2022 年列出的美国成人心脏移植候选者的测试数据集中，发现候选者风险评分 (US-CRS) 在预测 6 周内未移植的死亡方面更为准确。 Candidate Risk Score (US-CRS), was found to be more accurate at predicting death without transplant within 6 weeks in a test dataset of U.S. adult heart transplant candidates listed from 2019 to 2022.